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Diabetes and hepatitis C infection are both prevalent diseases worldwide, and are 
associated with increased morbidity and mortality. Most studies, but not all, have shown 
that patients with chronic hepatitis C are more prone to develop type 2 diabetes (T2D) 
compared to healthy controls, as well as when compared to patients with other liver 
diseases, including hepatitis B. Furthermore, epidemiological studies have revealed that 
patients with T2D may also be at higher risk for worse outcomes of their hepatitis C 
infection, including reduced rate of sustained virological response, progression to fibrosis 
and cirrhosis, and higher risk for development of hepatocellular carcinoma. Moreover, 
hepatitis C infection and mainly its treatment, interferon α, can trigger the development of 
type 1 diabetes. In this review, we discuss the existing data on this two-way association 
between diabetes and hepatitis C infection with emphasis on possible mechanisms. It 
remains to be determined whether the new curative therapies for chronic hepatitis C will 
improve outcomes in diabetic hepatitis C patients, and conversely whether treatment 
with Metformin will reduce complications from hepatitis C virus infection. We propose an 
algorithm for diabetes screening and follow-up in hepatitis C patients.
Keywords: type 1 diabetes, type 2 diabetes, hepatitis C virus, hepatitis C, insulin resistance, interferon alpha, 
hepatocellular carcinoma, outcomes, treatment
introduction
Type 2 diabetes (T2D) and hepatitis C are prevalent diseases worldwide. The World Health 
Organization (WHO) reported that 170 million people are chronically infected with hepatitis C virus 
(HCV) globally (1), and 347 million have diabetes mellitus (DM). Despite decreasing prevalence 
of hepatitis C infection in the United States, the disease burden continues to grow due to hepatitis 
C-related diseases (2). Studies have shown that more than one-third of patients with chronic HCV 
infection will develop at least one extrahepatic manifestation (3, 4).
A large number of studies report an increased risk for T2D in patients with chronic HCV infection 
(5). While a few studies could not confirm this association in the absence of liver dysfunction (6), the 
majority of studies strongly support this association. This association holds even when comparing 
patients with chronic HCV to patients with other progressive viral liver diseases (7, 8). There are also 
studies reporting T2D as a predisposing factor for HCV infection (9–11).
While insulin resistance (IR) and T2D are more frequently reported as complications of HCV 
infection, HCV is also known to be associated with several autoimmune manifestations, includ-
ing type 1 diabetes (T1D) (12, 13). Therapy for chronic HCV infection, in particular interferon 
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alpha (IFNα), can also trigger diabetes. The immunomodulatory 
effect of IFNα can induce or exacerbate autoimmune diseases. 
While interferon-induced thyroiditis (IIT) is the most frequently 
reported autoimmune complication of IFNα therapy (14, 15), 
other autoimmune conditions, such as T1D (16), systemic lupus 
erythematosus (17), rheumatoid arthritis (18), pernicious anemia 
(19), optic neuritis (20), vitiligo (21), and autoimmune hemolytic 
anemia (22) are also associated with HCV infection [for review, 
see Ref. (23)].
Recently, new non-interferon-based therapeutic regimens 
for hepatitis C have been introduced; however, chronic HCV 
infection and its sequelae remain a serious public health concern 
especially cirrhosis and hepatocellular carcinoma (HCC) which 
are the leading causes of death in patients with chronic HCV 
(24). Numerous studies illustrate that IR and T2D have a nega-
tive impact on clinical outcomes for patients with chronic HCV 
infection and it is possible that insulin-sensitizing therapy with 
metformin might be beneficial for reducing HCV complications. 
In this review, we analyze the literature linking HCV infection 
and its therapy – IFNα – with diabetes. We focus on the mecha-
nisms by which both HCV infection and IFNα treatment may 
contribute to the development of T2D and T1D (in this review, 
we refer to all forms of autoimmune diabetes as T1D), and the 
mechanisms by which diabetes can worsen outcomes in HCV 
infection.
We systematically searched PubMed databases from 1990 to 
2015.The search was limited to studies reported in English. The 
reference lists from identified studies were further searched for 
primary sources.
Type 2 Diabetes and insulin Resistance in 
HCv infection
Hepatitis C infection, insulin Resistance, and 
Type 2 Diabetes
An association between cirrhosis and glucose intolerance has 
long been known. Indeed, cirrhosis itself is “diabetogenic” with 
various studies describing the majority of cirrhotics as having 
impaired glucose tolerance (25–27). Beginning with Allison’s 
group in 1994 (26), epidemiological studies have since specifically 
linked HCV and HCV cirrhosis with DM (25, 26). The prevalence 
of DM, the majority assumed to be T2D, was significantly higher 
among patients with HCV cirrhosis than in patients with cir-
rhosis due to other etiologies (26). HCV infection precedes the 
diagnosis of T2D in as many as 73% of cases, further suggesting 
HCV’s pathogenic role in the development of T2D (28–30).
It is estimated that up to 33% of chronic hepatitis C patients 
have T2D (31). One meta-analysis of 34 studies showed a sig-
nificantly higher risk for T2D in HCV patients are compared to 
hepatitis B virus (HBV) patients [odds ratio (OR) 1.8], matched 
controls, and patients with other forms of chronic liver disease 
infection (5). Perhaps due to subtle variations in HCV genotype, 
ethnicity, severity of liver disease, and other variables, a few stud-
ies have found no association (32–34). Mangia et al. prospectively 
followed 385 non-cirrhotic hospitalized patients and concluded 
that the prevalence of DM was not significantly different than that 
in the general Italian population. A recent NHANES study also 
had conflicting results and showed that HCV infection was only 
associated with ALT and GGT elevations, not diabetes. However, 
there was still a clear trend for higher homeostatic model 
assessment-estimated insulin resistance (HOMA-IR) scores in 
both the HCV antibody and RNA-positive groups compared to 
controls (35). Regardless, the vast majority of studies have noted a 
2- to 10-fold increase of T2D in chronic HCV infection compared 
to other liver diseases (31, 36–38). The cumulative data suggest 
that T2D is approximately two to threefold more prevalent in 
HCV than in HBV infection. We therefore believe that the risk 
for T2D among HCV patients is significant and is more than just 
coincidental or cirrhosis-dependent (5, 39, 40).
Epidemiology
A positive association between chronic HCV infection and T2D 
has been consistently demonstrated across different ethnicities 
and geographic regions, in both developed and developing 
countries. The overall prevalence of DM among chronic HCV-
seropositive populations in North America, Europe, the Middle 
East, and Asia ranges from 13 to 33% (39, 41, 42). It is estimated 
that 20% of chronic HCV patients will develop cirrhosis and 
as many as ~50% of these patients will have T2D (26, 40). This 
translates into 47 million people worldwide and 750,000 people 
in the USA alone who are expected to develop HCV-associated 
T2D (31).
The landmark cross-sectional NHANES III study that surveyed 
9,841 US adults concluded that HCV-positive U.S. patients older 
than 40 years old had a threefold increased risk for T2D, compared 
to those without HCV (OR 3.77) (43). Other studies from the U.S. 
and abroad have corroborated this association between hepatitis 
C and T2D (7). The highest rate of HCV infection in the world 
is found in Egypt where 12% of its general population and up to 
40% of its older, rural population is HCV seropositive (41). The 
prevalence of DM is 25.4% among the HCV population in Egypt 
which indicates that chronic HCV patients are three times more 
likely to develop DM than the HCV seronegative population 
(38). In Italy, the frequency of HCV infection varies depending 
on certain geographic regions but ranges from 3 to 15% in the 
general population (44). One retrospective study showed that 
the relative risk for T2D in non-cirrhotic HCV patients was as 
high as 2.71 compared to that of non-cirrhotic HBV patients and 
1.81 compared to controls without hepatitis (45). Likewise, the 
prevalence of DM (presuming that the majority are type 2 DM) 
in South Korea is significantly increased in the chronic HCV 
patients (23.5%) compared to chronic HBV patients (8.2%) (46). 
In a Japanese retrospective study, the prevalence of DM (also 
presumed to be mostly T2D) was 20.9% among the non-cirrhotic 
HCV patients versus 11.9% among the non-cirrhotic HBV 
patients (47). Among the cirrhotic population, the prevalence 
rates for diabetes showed analogous findings; DM was found in 
30.8% of the HCV cirrhotics versus 11.9% of the HBV cirrhotics 
(47). The general trend, regardless of country of origin, suggests 
that T2D is approximately two to threefold more prevalent in 
HCV than in HBV infection.
The association between hepatitis C and T2D is also seen 
in the reverse direction, namely that diabetics are more prone 
September 2015 | Volume 6 | Article 1343
Hammerstad et al. Diabetes and hepatitis C
Frontiers in Endocrinology | www.frontiersin.org
to acquiring HCV. Although two small cohorts from Turkey 
and Nigeria failed to demonstrate an increased prevalence of 
hepatitis C among T2D patients, the vast majority of studies do. 
For instance, one US study showed the prevalence of hepatitis C 
to be 4.2% among diabetics compared to only 1.2% among the 
non-diabetic controls (7). By contrast, the prevalence of HBV 
in diabetics (0.3%) was not significantly increased compared to 
non-diabetics. A study in Taiwan that included 820 type 2 diabet-
ics showed that HCV seropositivity was 2.8 times greater among 
T2D patients than in non-diabetic controls (48). Similarly, a study 
from Italy showed that the prevalence of HCV infection among 
1,516 T2D patients was 7.6% compared to 2.3% in the non-
diabetic controls (49). Comparable trends were also observed 
in Pakistan with an OR for HCV infection of 3.03 among T2D 
patients (50).
Risk Factors for Type 2 Diabetes in HCV Patients
Age and gender
Age has been shown to be a risk factor and an independent pre-
dictor for the development of diabetes in chronic HCV patients, 
although not consistently in every study. When separated into 
quintiles by age, one study noted an increased frequency of 
diabetes in all HCV patients except in the youngest quintile that 
included those less than 38  years old (7). In the NHANES III 
cohort of almost 10,000 U.S. adults, the likelihood for T2D 
among HCV patients older than 40 years old was twofold com-
pared to those who were younger than 40 years old (43). When 
further evaluated for confounders, including ethnicity, sex, body 
mass index (BMI), and socioeconomic factors, the OR for T2D 
increased to 3.77 (43). Moreover, in Egypt it was also noted that 
the diabetic HCV patients were older than the non-diabetics 
(mean age 48.1 versus 40.7 years old) (41). Longer duration of 
hepatitis C infection has also been noted to increase the risk for 
diabetes.
Hepatitis C is more common among men than women (51), 
and male gender is also associated with more hepatitis C disease 
progression to fibrosis and cirrhosis. It is difficult, however, to 
precisely tease out the relative contribution of gender itself 
from confounders like fibrosis and hepatosteatosis, which are 
themselves markers of more severe liver disease and are associ-
ated with higher BMI, larger waist circumference, and a higher 
HOMA index (34).
Family history
Family history of diabetes has been demonstrated to be a risk fac-
tor for the development of T2D in HCV patients as in the general 
population (52). One case-control study showed that, among 45 
non-cirrhotic HCV-seropositive patients, 67% of those with T2D 
had a family history for diabetes versus only 7% of those without 
T2D (31). Another study showed a positive family history for 
diabetes in 29% of the HCV diabetic group while only 1.8% had 
pertinent family history in the non-diabetic group (40). This risk 
is comparable to the two to sixfold increased risk for T2D in the 
general non-HCV population who have a positive family history 
for diabetes (52). Across various ethnic groups (Pima Indians 
and populations in the US, Norway, South Africa, and the UK), 
the risk of developing diabetes is consistently increased among 
individuals with a positive family history and is up to 4.4-fold 
higher for individuals with a single diabetic parent (52).
Genotype
T2D in chronic HCV infection has also been correlated with spe-
cific HCV genotypes. In North America, ~70% of HCV patients 
are infected with genotype 1a and 1b while a mere 4% are infected 
with genotypes 2a (53). Despite these numbers, genotype 1 is 
relatively less associated with diabetes in the HCV population. 
For instance, one US case-control analysis showed that HCV 
genotype 2 was present in as many as 29% of 594 HCV-positive 
diabetic patients versus only 3% of the local HCV control patients 
(7). In Japan, HCV genotype 2 patients also have a higher rate of 
DM than genotype 1 (47). Non-genotype 3 HCV (particularly 
genotypes 1, 2, and 4) has been more closely associated with 
the development of T2D among the hepatitis C population, and 
interestingly, genotype 2a in particular has been preferentially 
associated with extrahepatic manifestations of HCV. Fewer cases 
of IR were consistently demonstrated among HCV genotype 3 
patients, even after adjusting for confounders like BMI and stage 
of fibrosis (52, 54). However, this has not been consistently dem-
onstrated in all studies (40). These discrepancies may be due to 
the differences in the number of patients with available genotype 
data.
Cirrhosis
Chronic HCV infection in the absence of cirrhosis or antiviral 
therapy is associated with T2D (7, 31, 40, 55). This indicates 
that it is not the stage of liver disease alone that influences the 
development of T2D. The presence of fibrosis and cirrhosis, 
however, in some studies has been shown to be an independent 
risk factor that contributes to the progression to T2D (31, 33, 40, 
42). Various studies have shown that the rate of T2D is higher 
among HCV cirrhotics than in other forms of cirrhosis, including 
cirrhosis caused by HBV, alcohol, or cholestatic disease (5, 40). 
Seventy to eighty percent of HCV cirrhotics have been reported 
to have glucose intolerance (31), and 50% of these cirrhotics have 
developed DM compared to only 9% of the non-HCV cirrhotics 
(26). This suggests a direct diabetogenic effect of the HCV beyond 
the damage to the liver. Furthermore, the rates of DM are even 
more increased on the background of higher grades of hepatic 
fibrosis, steatosis, or cirrhosis (31, 33, 40, 42, 56). For example, 
the prevalence of T2D was shown to increase with every rise in 
the fibrosis score of HCV patients with an OR of 3.83 (51). One 
prospective case series with 361 HCV patients from Pakistan 
showed an OR for T2D of 2.0 in HCV cirrhotics compared to 
that of HCV non-cirrhotics. Conversely, DM itself has recently 
been demonstrated to be hasten the progression of fibrosis and 
cirrhosis underscoring the bidirectionality of the association 
between chronic HCV infection and IR in chronic HCV infection 
(57) (see Hepatic Fibrosis and Cirrhosis).
Therapeutic regimen and virological response
Studies have shown that non-responders to HCV treatment 
have a greater incidence of DM and IR (28, 58). In a study of 
234 patients with chronic HCV infection who were treated with 
IFNα ±  ribavirin (RBV) and were followed for at least 3 years, 
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impaired fasting glucose was found in 34.1% of the non-sustained 
responders versus 14.6% of the patients with sustained virological 
response (SVR) (28). SVR is defined as undetectable viral load 
after 24 weeks of treatment. Furthermore, none of the patients with 
SVR developed DM while nine of the non-responders eventually 
developed T2D. In another study, treatment failure for HCV was 
associated with an OR of 2.81 for the development of new-onset 
IR (59) while other groups have demonstrated improvements in 
IR after viral clearance, strongly suggesting causality (i.e., that 
HCV is responsible for the IR) (28, 60). It is unclear, however, if 
IR is simply a consequence of poor response to IFN–RBV therapy 
or if it, on the contrary, mechanistically contributes to treatment 
resistance. Conversely, there is very strong evidence that hepatic 
disease progression and response to antiviral therapy are worse 
with concomitant DM (28, 54, 61) (see Virological Response to 
Antiviral Therapy). This two-way association between hepatitis 
C and diabetes further supports a potential direct role of HCV 
in IR and T2D.
Mechanisms
Hepatic fibrosis and cirrhosis are not the only mechanisms leading 
to glucose intolerance and frank DM in HCV patients (27, 62). It 
may be assumed that HCV infection could primarily predispose 
to T2D through the induction of hepatic steatosis. Chronic 
HCV infection after all carries a higher prevalence of steatosis 
(50%) compared to other liver diseases, including chronic HBV 
infection (18%) and autoimmune liver disease (16–21%) (63). 
Viral steatosis, however, is most frequently present in chronic 
infections with HCV genotype 3 and yet genotype 3 is the least 
associated with IR. Studies also suggest that viral steatosis may 
behave differently from metabolic steatosis and that the steatosis 
seen in non-genotype 3 HCV infections is more a marker and 
consequence of the underlying IR (27). There is growing evidence 
demonstrating that specific and direct effects of the HCV itself are 
responsible for triggering the development of T2D.
Increase in reactive oxygen species
The HCV genome comprises 10 mature proteins, including 
structural proteins (core, E1, E2, p7) and non-structural proteins 
(NS2–NS5). Various in vitro studies have demonstrated chronic 
background inflammation and an increase in mitochondrial 
reactive oxygen species (ROS) in HCV infection. NS3 and NS5, 
in particular, were shown to trigger oxidative stress responses. 
Human monocytes incubated with various HCV proteins 
demonstrated that NS3 selectively generated ROS by activation 
of NADPH oxidase, Nox2 (64). Human hepatoma Huh-7 cells 
transfected with an NS5A vector have shown an elevation of ROS 
with consequent activation of STAT-3 and NF-KB pathways (65) 
that then led to the release of an array of cytokines, including 
TNFα, TGFβ, IL-6, and IL-8. The structural core protein has also 
been demonstrated to induce an increase in ROS, mitochondrial 
dysfunction, and ER stress by possibly overwhelming glutathione 
stores and ER chaperones during viral replication (66, 67).
TNFα and other inflammatory cytokines
The intense inflammatory response to HCV is deemed central to 
the development of peripheral and hepatic IR in chronic HCV 
infection, primarily through disruptions in the insulin signaling 
pathway. Several studies have reported that TNFα can directly 
interfere with insulin signaling in HCV patients (68–70). Knobler 
and colleagues noted significantly more detectable serum TNFα 
(measured as soluble TNFR1 and 2) in diabetic HCV+ patients 
than in non-diabetic HCV+ patients (respectively, 74 versus 64%; 
p-value <0.0001), independent of prior IFNα treatment or cir-
rhosis (71). CRP was higher in both diabetic groups (regardless of 
HCV seropositivity) while levels of IL-6 and IL-8 remained con-
sistently low. Similar upregulation of TNFα and downregulation 
of IL-6 were observed in hepatic tissues of chronically infected 
HCV patients (72). Numerous animal and human studies with 
T2D patients have positively correlated TNFα with obesity and IR 
(73–76), and have implicated a role for TNFα in the pathogenesis 
of IR primarily through its postreceptor effects (71, 77). Animal 
pancreatic clamp studies have linked TNFα to increased IR and 
decreased glucose uptake (75). Similarly, in  vitro studies using 
cultured adipocytes stimulated with insulin showed that chronic 
TNFα exposure reduced tyrosine kinase activities and decreased 
autophosphorylation of the insulin receptor and tyrosine-phos-
phorylation of insulin receptor substrate 1 (IRS-1) (71, 77, 78). 
Moreover, incubation of Huh-7 hepatocytes with TNFα increased 
serine-phosphorylation of IRS-1 (79), also resulting in inhibi-
tion of the insulin signaling cascade. TNFα also downregulated 
GLUT4 mRNA expression in muscle and adipose tissues and has 
been implicated in reduced expression of IRS-1 and PPARs (80, 
81). A few studies have questioned the role of TNFα in IR and 
have shown no significant change in insulin signaling in skeletal 
muscle exposed to TNFα (82).
Direct alterations in insulin signaling by HCV
There is increasing evidence that HCV has direct effects on 
insulin signaling (Figure 1). One study found that, compared to 
control livers, the livers of the non-obese HCV patients showed a 
twofold decrease in insulin-stimulated tyrosine-phosphorylation 
of IRS-1 and a significantly blunted activation of two downstream 
targets that are critical for most of the metabolic effects of insulin: 
phosphoinositide 3-kinase (PI3-kinase) and Akt (Protein Kinase 
B, a downstream target of PI3-kinase) (37). An imbalance in the 
levels of activating tyrosine-phosphorylated IRS-1, the inhibitory 
serine-phosphorylated IRS-1, and threonine-phosphorylated 
Akt seems to play an integral part in the development of IR in 
hepatitis C (79, 83, 84).
Another group demonstrated that mice transgenic for the 
HCV core protein showed decreased expression of IRS-1 and 
IRS-2 (85). This group further showed that there was an accumu-
lation of ubiquitin-conjugated IRS-1 and IRS-2 in HepG2 human 
hepatic cells transfected with the HCV core protein. Proteasome-
mediated degradation was further suggested by the increased 
IRS-1 and IRS-2 expression levels after treatment with MG 132, 
a proteasome inhibitor (84, 85). The inhibition of IRS-1 may be 
due to mTOR activation by the HCV 2a core protein which then 
ultimately leads to IRS-1 degradation (84).
These findings were replicated in another in vitro study using 
Huh-7 cells transfected with the HCV 1b or 3a core proteins (86). 
Ubiquitin-mediated proteasomal degradation of IRS-1 via SOCS-7, 
a negative regulator of IRS expression, was found only in the 
HEPATOCYTE
Insulin receptor (IR)
↓IRS-1
PI3K
 Akt
↑SOCS
 mTOR
 Tyr– P
Ub
Ub
Thr– P
 Ser– P
HCV
C E NS
   Glucose uptake    Gluconeogenesis
FiGURe 1 | Potential mechanisms by which HCv directly affects the 
insulin signaling cascade. HCV infection of liver cells can lead to (1) 
decreased insulin receptor (IR in the figure) auto phosphorylation; (2) decreased 
IRS-1 activation due to increased serine-phosphorylation of IRS-1; (3) 
decreased IRS-1 levels due to increased ubiquitin-mediated proteasomal 
degradation induced by SOCS 3/7 and mTOR upregulation; (4) reduced Akt 
activity due to increased threonine-phosphorylation of Akt; (5) decreased 
GLUT4 expression; and (6) increased gluconeogenic enzymes (GC6P and 
PCK2). IR, insulin receptor; IRS-1, insulin receptor substrate-1; SOCS 3/7, 
suppressor of cytokine signaling; PI3K, phosphoinositide 3-kinase; mTOR, 
mammalian target of rapamycin; GC6P, glucose-6-phosphatase; PCK2, 
phosphoenolpyruvate carboxykinase 2.
September 2015 | Volume 6 | Article 1345
Hammerstad et al. Diabetes and hepatitis C
Frontiers in Endocrinology | www.frontiersin.org
cells transfected with the HCV 3a core protein. These HCV 3a 
transfected cells also had significantly reduced mRNA levels of 
PPARγ, an insulin-sensitizing nuclear receptor, and showed an 
inhibition in insulin-induced Akt phosphorylation. When subse-
quently treated with a PPARγ agonist, not only were these effects 
reversed but also IRS-1 levels were noted to be increased (86). 
These results suggest that there may be genotype-specific mecha-
nisms, although other groups have shown HCV 1b-mediated 
downregulation of IRS-1 by SOCS1 and SOCS3 (85).
Beta cell dysfunction
Histological evaluation of the pancreases of HCV-seropositive 
patients has shown evidence for pancreatic β-cells that are infected 
with HCV. These HCV-infected beta cells have been noted to have 
both morphological and functional defects, including a blunted 
insulin response to glucose (62). Narita’s group examined 131 
chronic HCV patients with normal fasting serum glucose levels 
who were later diagnosed as either glucose tolerant, glucose 
intolerant, or overt diabetic after a 75  g oral glucose tolerance 
test (OGTT). These patients were further evaluated for various 
parameters of IR and of beta cell function (HOMA-β, C-peptide 
and insulin levels, ΔC-peptide 30, insulinogenic index). 
Significant decreases in the ΔC-peptide 30 and the insulinogenic 
index, both markers of early phase pancreatic insulin secretion, 
were consistently noted in the diabetic group suggesting a 
direct effect of HCV on beta cells (87). Others have suggested 
that proinflammatory cytokines secreted in chronically infected 
HCV patients, such as TNFα, may also affect beta cell function 
by disrupting insulin signaling/secretion and by sensitizing the 
beta cell to the toxic effects of free radicals (76, 88). These findings 
support the notion that HCV infection induces significant beta 
cell dysfunction either directly or through cytokine release.
iFNα Therapy – insulin Resistance and  
Type 2 Diabetes
The literature is mixed on the effects of IFNα on IR. Some studies 
have shown an improvement in glucose levels during treatment of 
HCV infection. Huang et al. observed that 63 out of 180 hepatitis 
C patients with pre-diabetes (34.8%) became normoglycemic 
after PegIFNα–RBV therapy, while 10 (5.5%) developed DM (89).
It has also been documented that SVR may be an important 
factor in the reduction of IR after IFNα therapy (89, 90). The 
results from a cohort that included patients without diabetes, 
who were treated with IFNα for hepatitis C, showed that 143 
out of 2,842 patients developed T2D during a mean observation 
time of 6.4 years. Predictive factors for development of diabetes 
in this study were older age, histological changes (cirrhosis), and 
non-SVR (60).
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Also, injection of IFNα to healthy persons impaired glucose 
tolerance and insulin sensitivity, stimulated counter regulatory 
hormone secretion, and stimulated insulin clearance (91). In 
contrary, Ito et al. could not reveal any effect on insulin sensitivity 
and glucose tolerance at 3-month follow-up after IFNα treatment 
for hepatitis C (92).
Oral administration of low-dose IFNα (5,000 U) to patients 
with newly diagnosed T1D was shown to maintain more beta cell 
function after 1 year compared to high-dose (30,000 U) groups 
(93, 94). However, these studies had methodological limitations 
and there were no statistically significant differences in HbA1c or 
insulin dose between the two groups (93, 94).
Pancreatic islets Autoimmunity – Type 1 
Diabetes and Hepatitis C virus infection of 
the islets
Even though HCV is a liver-tropic pathogen, the antigen and viral 
sequences have been detected in other organs, such as the thyroid 
(95) and the pancreas (62, 96). Using RT-PCR on pancreatic tis-
sue removed at autopsy from HCV-infected individuals, Yan et al. 
showed the presence of HCV RNA in all nine pancreata tested 
(96). However, the viral load was lower than in the liver. These 
results were confirmed in 5/9 pancreata by in situ hybridization 
(ISH), and by immunohistochemistry (IHC) in 6/9 pancreata 
(96). The authors suggested that the infected pancreas might 
act as a reservoir for HCV and may play a role in persistence of 
infection. Conversely, it is plausible that the infection may cause 
pancreatic islet dysfunction and/or trigger islet autoimmunity. 
Interestingly, epidemiological studies have shown a possible 
relationship between hepatitis C and pancreatic carcinoma (97), 
also suggesting direct infection of the pancreas by HCV and 
induction of local inflammation (98). If indeed direct infection 
of islets or acinar cells by HCV is confirmed, it is possible that it 
can trigger autoimmunity in susceptible individuals by inducing 
local inflammation with cytokine and chemokine secretion (also 
called “bystander mechanism”).
HCv infection and Type 1 Diabetes
Epidemiological studies have suggested but not confirmed an 
association between HCV infection and islet autoimmunity. In 
several studies, the frequency of T1D autoantibodies was not 
significantly higher in chronic HCV-infected patients selected 
for IFNα therapy than that in controls (99, 100). Hieronimus 
et  al. reported the presence of glutamic-acid decarboxylase 
antibodies (GAD-antibodies) in 1 out of 47 untreated HCV 
patients with known T1D (99). Piquer and colleagues showed the 
presence of GAD-antibodies in 4 out of 277 (1.4%) non-diabetic 
HCV patients, and 1 out of 273 (0.4%) in control population. 
However, this difference did not reach statistical significance 
(101). Nevertheless, there are several cases of T1D reported in 
the literature that were associated with acute hepatitis C infec-
tion. Chen reported a case of a male patient who developed 
acute hepatitis C after blood transfusion. The patient presented 
GAD-antibodies and islet cell antibodies (ICA Abs) 4 weeks after 
transfusion, and developed T1D 1 year later (12). The patient had 
HLA DR3 and DR7, which are not associated with T1D in China. 
Another case, a 22-year-old female with type 1 diabetes and acute 
hepatitis C, was reported by Masuda (13). Therefore, it seems that 
the majority of the risk for T1D in hepatitis C patients is due 
to IFNα therapy (see below); however, HCV infection itself may 
also contribute synergistically to the association, possible by local 
production of IFNα in the islets if HCV indeed is proven to infect 
the islets (Figure 2).
iFNα Therapy in HCv infection and Type 1 
Diabetes
Interferon alpha was discovered more than 50 years ago (102), 
and is now recognized as a key component of the innate immune 
response and the first line of defense against viral infections. 
IFNα therapy was shown to be particularly effective in HCV 
infection. Indeed, hepatitis C is the most frequent indication for 
IFNα therapy (103), even though recently non-interferon-based 
therapies for HCV infection have been replaced interferon-based 
therapies. IFNα treatment has considerably improved the out-
comes in patients with chronic HCV infection, however, with its 
potent immunomodulatory effect it may contribute to develop-
ment of autoimmunity.
Epidemiology
The first case of IFNα-induced T1D was reported by Fabris et al. 
(104). Although the exact incidence of IFNα-induced diabetes 
is unknown, several large retrospective studies investigating 
adverse effects of IFNα in patients with chronic viral hepatitis, 
mainly hepatitis C, reported incidences of 0.08% (10/11.241) 
(105) in Italy, and 0.7 (5/667)–0.96% (12/1.250) in Japan (106, 
107). Nakamura et al., in a nationwide study in Japan, identified 
91 patients with IFNα-induced T1D (108). Furthermore, a Dutch 
study reported development of T1D in 5 out of 189 patients 
(2.6%) treated with Peg-IFN + RBV (109). In a study from Spain, 
including 46 patients, no evidence of increased prevalence of 
beta cell autoimmunity was found 6 and 12 months after IFNα 
therapy (101).
In most reported cases, the onset of T1D occurred during or 
shortly after treatment with IFNα [reviewed in Ref. (110)]. To 
date, there are more than 45 case reports of T1D developing 
after treatment with IFNα. The clinical presentation is usually of 
an acute onset as is typical for T1D (108). The levels of GAD-
antibodies were reported to be significantly higher in IFN-induced 
T1D compared to classical T1D (106). It is important to suspect 
T1D in HCV patients experiencing polyuria and polydypsia, or 
other T1D symptoms after initiation of IFNα therapy. Of note, 
treatment with IFNα is associated with many side effects such 
as flu-like symptoms, gastrointestinal (GI) symptoms, and head-
aches (111) that can mask the symptoms of diabetes, resulting in 
delayed diagnosis and complications.
Risk Factors for IFN-Induced Type 1 Diabetes
Age and gender
Whether age is a risk factor for IFN-induced T1D is difficult to 
answer since the age of onset of T1D in HCV patients likely reflects 
the age at which IFNα was initiated. The mean age at the onset of 
IFN-induced T1D was 56 years in a nationwide survey in Japan 
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that included 91 patients who developed interferon-induced T1D 
(most received IFNα for HCV infection) (106).
The reported female to male (F/M) ratio of IFN-induced T1D 
in the same survey in Japan was 0.90, which is lower than the 
1.4–1.5 F/M ratio for T1D in the Japanese population (106) and 
likely reflects the male preponderance of HCV. Another study also 
found no significant difference in the male and female frequency 
in children or adults who developed IFN-induced T1D (112). 
Similarly, the F/M ratio for IFN-induced T1D in Europe (~0.5) 
was also lower than that for classical T1D (~1) (105, 109). This 
ratio may reflect the gender distribution of hepatitis C as numer-
ous large cohorts reported that overall two-third of reported cases 
of chronic HCV infection were males [for review, see Ref. (113)].
Preexisting islet autoantibodies
Autoantibodies are often reported in both adults and children 
with HCV infection. Wesche et al. reported development of islet 
autoantibodies in 9.7% (6/62) of patients after initiation of IFNα 
therapy (114). In another cohort, 2.5% (5/186) non-diabetic 
patients who received Peg-IFN + RBV developed T1D, and 1.6% 
(2/186) developed T2D (109). Two out of the five patients with 
IFN-induced T1D were tested positive for islet antibodies at the 
baseline prior to initiation of interferon therapy. Results from 
a recent cohort reported development of T1D in 1 out of 114 
children (age 4–17 years) with chronic hepatitis C treated with 
Peg-IFN, while 9.3% had positive diabetes-related antibodies at 
baseline (4% with GAD-antibodies) (112).
Even though islets autoantibodies, diagnostic of T1D, have 
not been commonly measured pre- and post-treatment with 
IFNα, seroconversion has been observed following IFNα therapy. 
Fabris reported clinical features of 31 cases of IFN-induced T1D 
of whom 23 were treated for chronic hepatitis C (1992–2002) 
(16). For those who were tested for antibodies, markers for pan-
creatic islet autoimmunity were present prior to IFNα therapy in 
50% of cases with IFN-induced T1D. These data are consistent 
with the well-known fact that islet autoantibodies are the best 
biomarkers of genetic risk factors for T1D. These findings are 
similar to those observed for IFNα-induced thyroiditis where 
thyroid Abs were shown to be the strongest risk factor for IFN-
induced thyroiditis (115).
Family history
One study that examined family history in patients that developed 
T1D during or following IFNα therapy did not find history of 
T1D in first degree relatives of patients with IFNα-induced T1D 
(108). It is, however, interesting that 15% of patients with chronic 
HCV infection had T2D, and 23% had first degree family history 
of T2D (108). Among 31 cases of IFN-induced T1D reported by 
Fabris, family history of T1D was reported in 3/31 (9%) patients 
who developed IFN-induced T1D and family history of T2D was 
reported in 6/31 (19%) (16). Koivisto postulated that the impair-
ment in insulin sensitivity (91), and the resulting stimulation of 
beta cells may make islets more vulnerable to destructive process 
of IFNα therapy (116).
Viral genotype
The HCV genome was determined by Choo et al. (117). Based 
on the identification of genomic differences, HCV has been clas-
sified into distinct subtypes. Genotype 1 (1a and 1b) is the most 
common form in the USA and Europe (118), while genotype 1b is 
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common in Japan. Genotype 2 is the second commonest strain in 
North America, Europe, and Japan (119, 120). Genetic heteroge-
neity of HCV may account for some of the differences in disease 
outcome and response to treatment observed in HCV-infected 
individuals (121).
In the Japanese nationwide survey, genotype 1b was most 
frequently detected (81%) in patients that developed IFN-
induced T1D (106), but this likely reflected the fact that 
genotype 1b is the most prevalent HCV subtype in the Japanese 
(121) and Chinese populations (122). Patients with genotype 1 
that is more resistant to therapy, usually receive higher doses 
of IFNα and for longer duration contributing to adverse effects 
(113). In a recent study, Nakanishi and co-workers could not 
find an association between genotype 1b and the development 
of T1D; however, the study was limited as the control group 
included very few patients (106). Similarly, Hasham et  al. 
reported that 74% of patients with IFN-induced thyroiditis 
were infected with HCV genotype 1, however, 76% of hepatitis 
C controls also had genotype 1 (123). Thus, viral genotype does 
not contribute to the association of interferon therapy in HCV 
patients with T1D.
Therapeutic regimen and virological response to therapy
Data regarding the impact of therapeutic regimen and SVR on 
development of IFN-induced diabetes are difficult to compare 
as different forms, dosages, and durations of IFN therapy were 
used in different studies. Until 2011, the standard IFNα regimen 
for HCV infection included pegylated IFNα (peg-IFN) 2a in 
combination with RBV, with genotype-dependent dosage and 
duration (124). Genotype 1 has the lowest SVR to this regimen 
compared to genotypes 2 and 3, and it requires higher doses of 
IFNα. This might contribute to more side effects (113, 125). RBV 
also has immunomodulatory effects, but RBV is rarely used as 
monotherapy. However, there is a case report describing a patient 
who developed T1D after RBV was added to Peg-IFN (126).
The median time from initiation of IFN therapy to the onset 
of T1D was 8 months in a Japanese cohort, and was significantly 
shorter in those who were treated with the Peg-IFNα in com-
bination with RBV compared to those who were treated with 
non-Peg-IFN in mono therapy (108). Interestingly, almost 60% of 
patients who developed T1D were negative for HCV RNA at the 
onset of T1D. Overall, the mean latency period in reported cases 
of IFN-induced T1D was 5  months and ranged from 10  days 
to 4 years [reviewed in Ref. (16)]. However, no correlation was 
found between the rate of virological response and the latency 
of development of T1D (16, 108). Supporting this observation is 
an Italian cohort that did not show a significant difference in the 
incidence of glucose abnormalities between long-term respond-
ers and non-responders (58).
The current guidelines for treatment of chronic HCV infec-
tion recommend using protease inhibitors in combination with 
Peg-IFN with or without RBV for genotype 1 (127). However, 
protease inhibitors have side effects too, and recently a case of 
T1D induced shortly after triple therapy was reported (128). 
Further studies are needed to determine the impact of protease 
inhibitors in combination with IFN, or in monotherapy, on the 
development of autoimmunity. In addition, as the therapy for 
chronic HCV infection switches to non-interferon-based thera-
pies, it is possible that T1D will no longer be triggered by therapy 
for hepatitis C.
Genetic factors
Genetic susceptibility plays a major role in the etiology of T1D 
(129). Therefore, genetic predisposition may also play a role in 
the etiology of IFNα-induced T1D. In a Japanese cohort, HLA-
A*2402 [associated with T1D in Japan (130)] was shown to be 
associated with the development of T1D in patients treated with 
IFNα (106). It is intriguing that HLA-A24 has also been shown to 
be associated with the development of IFNα-induced thyroiditis 
in Japan (131), suggesting a general role for HLA-A24 in IFNα-
induced autoimmunity. The frequency of HLA-DR4 and DR9 
(also susceptibility genes for T1D in Japan), as well as DR13, was 
also significantly higher in patients with IFNα-induced T1D when 
compared to healthy controls (108). Moreover, HLA-DR13 was 
also significantly more frequent in patients with IFNα-induced 
T1D compared to patients with classical T1D, suggesting a direct 
role in IFNα-induced autoimmunity through an environmental–
genetic interaction (108). Studies and results from reported cases, 
including patients with different ethnicity, showed association 
between IFN-induced T1D and classical T1D HLA haplotypes 
(DR3, DR4, DQ8) (16, 109, 110).
Interferon alpha may also trigger or accelerate disease devel-
opment in genetically predisposed individuals. We previously 
showed that injecting IFNα to NOD H2h4 mice, a strain geneti-
cally susceptible to spontaneous autoimmune thyroiditis, caused 
a higher frequency of autoimmune thyroiditis. These findings 
support the notion that IFNα triggers or accelerates autoimmun-
ity in genetically susceptible individuals (132). However, similar 
studies have not been performed in mice genetically predisposed 
to autoimmune diabetes.
Taken together, these data support two potential mechanisms 
by which genetic susceptibility can contribute to IFN-induced 
T1D: (1) some individuals inherit classical T1D susceptibility 
genes and IFNα simply triggers or accelerates the progression of 
T1D in them; alternatively, (2) other individuals inherit genetic 
variants that uniquely predispose to IFNα-induced autoimmunity.
Mechanisms
The mechanisms by which IFNα can induce T1D have not been 
thoroughly studied (Figure 2). IFNα has diverse effects on the 
immune system that can be implicated in the development of 
autoimmunity. By binding to its receptor, IFNα activates the 
JAK–STAT pathway (133–135), leading to expression of inter-
feron-stimulated genes (ISGs), including cytokines and adhesion 
molecules genes. These proinflammatory cytokines can trigger 
autoimmunity in genetically susceptible individuals (Figure 2).
A direct effect of IFNα on the pancreas might also trigger 
T1D. Indeed, several studies have shown elevated levels of IFNα 
in the pancreas of patients with a recent onset of T1D (136–138). 
Transgenic mice over-expressing IFNα in their beta cells devel-
oped hypoinsulinemic diabetes associated with islets inflamma-
tion, demonstrating that IFNα can trigger T1D locally by direct 
effects on the islets. This inflammatory disease process was pre-
vented through the use of an IFNα neutralizing antibody (139). 
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Our group has previously shown similar results in transgenic 
mice over-producing IFNα in the thyroid; these transgenic mice 
developed severe inflammatory thyroiditis (140). In our thyroidal 
model, IFNα triggered the recruitment of inflammatory cells 
through the induction of various cytokines and chemokines, 
and it activated cytotoxic T cells causing thyroid cell necrosis 
(Figure 2). Moreover, we were also able to show direct toxic effects 
of IFNα on thyroid cells (140). If a similar mechanism occurs in 
the islets, it is possible that IFNα can also induce toxic effects in 
islet cells. Li et al. demonstrated that blockade of IFNα signaling 
in 2- to 3-week-old NOD mice by anti-IFNAR1 mAb resulted in 
delayed onset and decreased incidence of diabetes (141). This was 
accompanied by an increase in the number of immature dendritic 
cells in draining popliteal lymph nodes and enhanced production 
of the cytokines IL-4 and IL-10. Furthermore, interferon regula-
tory factor 1-deficient NOD mice were protected from T1D (142).
Interferon alpha modulates the ability of immune effector 
cells to interact with infected cells, partly through upregulation 
of MHC class I molecules on target infected cells (143). Moreover, 
overexpression of MHC class I antigens is associated with activa-
tion of cytotoxic T cells. Upregulation of MHC class I molecule 
expression on islets cells is a prominent, early feature during the 
development of T1D (144), and it is possible that this is mediated 
by IFNα. In one study, 33 of 34 pancreata removed at necropsy 
from patients with T1D revealed beta cells that were positive for 
immunoreactive IFNα and showed hyperexpression of MHC 
class I antigens (136). Moreover, type I interferons decrease 
regulatory T cell activation, another effect that may play a role 
in development of autoimmunity (145, 146). In contrast to these 
data, a recent study showed an increase in the number of regula-
tory T cells and a decrease in CD8+ T cells in the livers of mice 
treated with IFNα (147).
effects of insulin Resistance and Type 2 
Diabetes on Outcome of Chronic HCv 
infection
While HCV infection has been demonstrated to be a risk factor 
for T2D (see Type 2 Diabetes and Insulin Resistance in HCV 
Infection), patients with HCV and IR have also been shown to 
have significantly worse clinical outcomes. This two-way associa-
tion further exemplifies the integral role of IR in HCV infection. 
IR is associated with increased liver fibrosis, reduced virological 
response to antiviral therapy, and higher rates of HCC. There 
is also some evidence that IR increases the risk for liver-related 
death and is associated with shorter time to transplantation (148).
Association of Diabetes/insulin Resistance with 
worse Outcomes in Hepatitis C
Hepatic Fibrosis and Cirrhosis
A number of factors are known to increase the risk of liver fibrosis 
and subsequent cirrhosis. These include longer duration of infec-
tion, older age at time of exposure, male gender, co-infection with 
other viruses, and alcohol consumption (149, 150). In addition 
to these factors, IR is increasingly recognized as a separate risk 
factor for fibrosis progression and cirrhosis.
Two studies by Hui et al. demonstrated that IR is an independ-
ent predictor of fibrosis in chronic HCV infection (54, 151). 
Similarly, Hsu et al. found a strong association between diabetes 
and severity of fibrosis (152). A recent, large cohort study from 
Taiwan also concluded that patients with chronic HCV infection 
who developed diabetes had a two to threefold increased risk 
for development of cirrhosis and hepatic decompensation (57). 
However, these findings are not uniform and a few studies failed 
to show this correlation (153–155). While Svegliati-Baroni et al. 
did not find an association between HOMA-IR and liver fibrosis, 
they did find post-load IR to be a predictor of fibrosis progres-
sion correlation (153). Overall, the majority of studies support 
the notion that IR and diabetes predispose to liver fibrosis and 
cirrhosis.
Virological Response to Antiviral Therapy
While there is significant evidence to suggest that DM worsens 
response to antiviral therapy, a few studies could not confirm this 
relationship. A large study of 330 patients found that reduced 
HOMA-IR correlated with lower rates of SVR, particularly in 
patients with “difficult to treat” chronic HCV populations, includ-
ing cirrhotics, the overweight, and HIV-coinfected individuals 
(156). Other studies suggested that HOMA-IR only predicts 
treatment response in patients with genotype 1 HCV (157). 
An Italian study of 412 patients showed a trend for association 
(albeit not statistically significant) between higher HOMA-IR 
and reduced SVR (p = 0.06) (158).
To resolve these conflicting data, a recent meta-analysis of 14 
studies showed that patients with IR treated with pegIFN–RBV 
had a 20% lower rate of SVR compared to patients without IR 
(95% CI: −29.9 to −9.4%, p < 0.001). In addition, responders had 
a lower HOMA-IR compared to non-responders (mean differ-
ence: −0.92, 95% CI: −1.53 to −0.32, p < 0.001) (159).
Hepatocellular Carcinoma
Hepatocellular carcinoma is the third leading cause of cancer-
related mortality worldwide (160). Chronic HCV infection is 
an established risk factor for HCC. Recent studies suggest that 
diabetes also increases the risk of malignancy, including HCC 
(148, 161, 162). Additionally, diabetes is a risk factor for HCC-
related mortality (163).
A recent Taiwanese study found that HCV patients with diabe-
tes had a hazard ratio of 1.73 for HCC compared to non-diabetic 
HCV patients (161). Of note, patients with hepatitis B did not 
demonstrate a similar increase in HCC incidence (161). Another 
study of HCV patients with Ishak fibrosis score 4–6 found HCC 
incidence to be 11.4% in diabetics, and 5.0% in non-diabetics 
(162). The relationship persisted even when controlling for albu-
min, bilirubin, and platelet count. The degree of IR also appears 
to correlate with HCC risk. A study from France in patients with 
HCV cirrhosis found the 5-year incidence of HCC to be 7, 18, 
and 27% for the lowest, middle, and highest tertile of HOMA-IR, 
respectively. In a multivariate analysis, HOMA-IR was still pre-
dictive of HCC incidence, albeit with a hazard ratio of 1.1 (148).
While the majority of published studies support an associa-
tion between diabetes and HCC in HCV patients, there are a few 
reports showing otherwise. However, a 2006 literature review 
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found an association between diabetes and HCV-related HCC 
in 9 of 13 case-control studies and 7 of 13 cohort studies (164). 
Despite some inconsistencies, the pooled risk ratio and pooled 
OR were both significant at 2.5.
Mechanisms of Accelerated Disease 
Progression in HCv Patients with Diabetes and 
insulin Resistance
Hepatic Fibrosis and Cirrhosis
Liver fibrosis is a reversible wound-healing response to hepatic 
cell injury. Parenchymal cell regeneration in response to acute 
injury generally results in minimal deposition of extracellular 
matrix (ECM). However, chronic hepatic injury disrupts the 
balance between liver repair and scar formation. Hepatocytes 
are replaced with excessive ECM produced primarily by hepatic 
stellate cells (HSC) (165).
Excessive HSC activation is one proposed mechanism by which 
IR can induce fibrosis. Supporting this hypothesis, in vitro studies 
showed that hyperglycemia and hyperinsulinemia upregulate the 
secretion of connective tissue growth factor mRNA, a growth fac-
tor involved in HSC activation and subsequent fibrogenesis (166). 
In addition, insulin can directly stimulate HSC proliferation in a 
dose-dependent fashion (167).
Hepatitis C virus is associated with accelerated steatosis that 
is mediated through increased production of lipogenic sub-
strate, upregulation of lipogenesis, and disruptions of fatty acid 
metabolism (168). The magnitude of HCV-related steatosis is 
compounded by IR. IR activates the lipid biosynthetic pathway in 
the liver resulting in dyslipidemia and increased steatosis, which 
can accelerate liver fibrosis (169). Decreased insulin sensitivity 
also increases release of free fatty acids from adipose leading 
to increased hepatic lipid deposition (170). Enhanced hepatic 
lipid deposition and steatosis are independently associated with 
increased fibrosis in patients with genotype 1 HCV (171).
Lastly, a reciprocal regulation between HCV and SNF1/AMP 
kinase-related kinase (SNARK) promotes TGF-β signaling, a 
major driver of hepatic fibrogenesis. In vitro studies have shown 
that metformin suppressed both HCV replication and SNARK-
mediated enhancement of TGF-β signaling (172).
Virological Response to Antiviral Therapy
IR is associated with increased levels of protein tyrosine phos-
phatases (PTP). PTPs inhibit phosphorylation of signal trans-
ducers and activators of transcription (STATs), thus preventing 
activation of a group of key transcription factors in the interferon 
signaling pathway that can lead to decreased effectiveness of 
IFNα therapy and lower rates of SVR (173, 174). This has been 
corroborated by an in vitro study that demonstrated an insulin-
driven dose-dependent decreased expression of IFN-stimulated 
genes, including PKR, MxA, and OAS-1 (175).
In  vitro studies have shown that metformin downregulates 
PTP-1B and improves response to IFNα in liver cell lines (174), 
and that metformin inhibited HCV replication by activating AKT 
(176). However, clinical trials examining the role of metformin 
in antiviral treatment regimens provided mixed results (157). 
The TRIC-1 study group compared metformin versus placebo 
in HCV patients treated with pegINF–RBV. While intention 
to treat analysis showed no effect of metformin, per protocol 
analysis displayed a 10% absolute increase in treatment success 
with metformin (157). Moreover, subgroup analysis of females 
showed an SVR of 57.7% with metformin versus 28.6% with pla-
cebo (p = 0.03). A recent open-label study by Yu et al. found that 
addition of metformin to pegIFN–RBV resulted in 59.2% SVR 
compared to 38.8% SVR without metformin (177). In contrast, 
a placebo-controlled trial by Sharifi and colleagues found no 
correlation (178).
Additionally, HCV replication is thought to be downregulated 
by p21-activated kinase 1 (PAK1). IR may reduce PAK1 activ-
ity leading to upregulation of HCV replication (179, 180). IR is 
also associated with increased viral load (181) and progression 
of fibrosis (54, 152), which independently influence response to 
interferon-based therapy (182). It remains to be determined the 
extent to which SVR will continue to be affected by IR when using 
novel anti-HCV regimens.
Hepatocellular Carcinoma
Patients with diabetes are at increased risk for various types of 
malignancies (183–185). HCC appears to be one of the malignan-
cies most strongly linked to diabetes with a relative risk of 2.5 (184, 
185). Chronic HCV infection thus promotes HCC both directly 
and indirectly through the virus’s diabetogenic effects (184). 
While the exact mechanisms have yet to be elucidated, insulin, 
insulin-like growth factor (IGF), and chronic inflammation have 
all been implicated in tumorigenesis (184, 186). Additionally, 
hyperglycemia is thought to promote tumorigenesis by providing 
the metabolic substrate necessary for cancer cell survival (184).
The insulin receptor is regulated by alternative splicing mecha-
nisms to yield two isoforms, IR-A and IR-B. IR-A expression is 
increased in cancer cells, including HCC, and primarily promotes 
the mitogenic role of insulin, while IR-B primarily controls insulin’s 
metabolic effects (187, 188). High insulin levels in the setting of IR 
likely activate the IR-A pathway driving tumorigenesis, while the 
IR-B pathway remains downregulated. This phenomenon would 
be amplified in the setting of IR-A upregulation, which occurs in 
cancer cells including HCC (187). Chettouh et al. demonstrated 
that HCC cell lines with enhanced IR-A expression proliferated 
in response to insulin while normal human hepatocytes did not 
(187). Insulin binds to its receptor, likely IR-A, in the setting of 
tumorigenesis, and activates downstream signaling cascades via 
insulin receptor substrate (IRS) proteins (189). Indeed, levels of IRS 
proteins are elevated in human cancers, including HCC (181). IRS 
proteins can activate mitogen-activated protein kinase (MAPK) 
and the phosphoinositol-3-kinase (PI3K)/AKT pathway (186, 188, 
189). These pathways are involved in cell growth and proliferation 
and inhibition of apoptosis as shown in Figure 3 (186, 188, 189).
Hyperinsulinemia also augments IGF-1 receptor (IGF-1R) 
signaling through increased hepatic production of IGF-1 and 
decreased hepatic production of IGF-binding proteins (IGF-BPs), 
thereby increasing levels of free IGF-1 (184, 190). Similar to activa-
tion of IR-A, IGF-1R activation leads to stimulation of the MAPK 
and PI3K/AKT pathways (Figure 3) (184, 186, 189). The LeRoith 
group demonstrated that administration of IGF-1 to liver-specific 
IGF-1-deficient (LID) mice with orthotopically implanted colon 
adenocarcinoma resulted in increased liver metastasis compared 
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FiGURe 3 | Possible mechanisms linking diabetes to accelerated 
cancer development. Binding of insulin to the insulin receptor (IR in the 
figure), likely IR-A and/or binding of IGF-1 to the IGF-1 receptor activate MAPK 
and PI3K/AKT signaling pathways leading to increased cell proliferation and 
decreased apoptosis. Hyperglycemia and chronic inflammation also contribute 
to cancer progression through other mechanisms. The mechanisms by which 
HCV promotes the development of HCC were not included in this figure. IGF-1, 
insulin-like growth factor 1; IGF-1R, insulin-like growth factor 1 receptor; IR-A, 
insulin receptor A; MAPK, mitogen-activated protein kinase; PI3K, 
phosphoinositide 3-kinase; AKT, protein kinase B.
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with saline controls (191). Therefore, it is possible that elevated 
levels of IGF-1 induced by hyperinsulinemia could also promote 
HCC growth. Notably, IGF-1 and IGF-BPs are primarily produced 
in the liver. Greater than 90% of patients with HCC suffer from 
cirrhosis (192), which may impair IGF-1 and IGF-BP synthesis.
Diabetes and obesity are states of chronic inflammation asso-
ciated with elevated levels of leptin and low levels of adiponectin 
(193). Leptin is a proinflammatory adipokine that is linked to cell 
proliferation and invasion of cancer cells, while adiponectin is 
an anti-inflammatory adipokine that has been linked to reduced 
tumor growth (184, 188, 193). While the precise relationship 
between leptin, adiponectin, and HCC is still poorly understood 
(194), the chronic inflammation associated with diabetes may 
also promote HCC.
Further supporting the association between HCC and diabetes 
is recent evidence that metformin decreases the risk of HCC in 
patients with chronic HCV infection. A 2009 study of patients 
with HCV cirrhosis and diabetes found the 5-year incidence of 
HCC to be 9.5% for patients treated with metformin versus 31.2% 
without metformin therapy (p = 0.001) (182). Several additional 
studies, including a recent meta-analysis, show similar findings 
(183, 184). While clinical data are suggestive that metformin 
has anti-neoplastic properties, supporting laboratory models 
have been criticized for using concentrations of metformin that 
greatly exceed clinical dosing (195). Further studies are needed 
to determine whether metformin’s anti-neoplastic effects are 
secondary to direct effects of metformin on hepatocytes or due 
to the insulin-sensitizing effect of metformin.
Screening for Diabetes in HCv Patients 
and Therapeutic Considerations
Screening
Who?
As summarized above, epidemiological data clearly show that 
patients with chronic HCV infection are more susceptible to 
develop T2D. Moreover, there is negative impact of IR and dia-
betes on virological response and long-term outcomes of HCV 
infection. Therefore, we recommend screening for diabetes in all 
HCV-infected patients regardless of age or medical history. There 
is also epidemiological evidence for increased prevalence of hepa-
titis C in patients with diabetes, and some authors find it reason-
able to screen patients with diabetes and persistently elevated ALT 
for HCV (196). T2D patients frequently present with abnormal 
liver enzymes (197); however, in most cases, the elevated ALT 
levels may represent non-alcoholic fatty liver disease (NAFLD). 
Still testing for hepatitis C could be considered in diabetic patients 
with elevated liver enzymes, especially in cases with no evidence of 
NAFLD. We recommend that each case be evaluated individually.
Whether screening for islet autoantibodies is necessary prior 
to IFN therapy, which has been shown to trigger islet autoim-
munity, is unclear. Fabris reported the presence of autoantibodies 
in 50% of patients with IFN-induced T1D (16). In our opinion, 
screening for islet antibodies should be considered in patients 
with increased risk for T1D, such as patients with first degree rela-
tives with T1D, patients with known autoimmune conditions, and 
HCV patients receiving IFNα (Figure 4). Pretreatment screening 
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de (3) 
Screen for Islet Abs (4)
Negave
Negave
Screen for DM           
Every 6-12 months
Negave
Yes Yes
Treat as T1D
PosivePosive
Screen for DM              
Every 3 months (5)             
During the 1st first year, 
then every 6-12 months
Screen for Islet Abs (4)
No
High-risk T1D (2)
and IFNα Therapy
FiGURe 4 | Algorithm for screening for diabetes in hepatitis C patients. (1) 
Screen for DM: fasting blood sugar (FBS) and/or oral glucose tolerance test 
(OGTT). HbA 1c might be considered if the measurement methods are well 
established. (2) High risk Type 1 diabetes patients are defined as individuals with 
first degree relatives with type 1 diabetes (T1D); patients with other autoimmune 
conditions; or patients might be considered as high risk, if IFNα therapy is 
considered. (3) Fasting C-peptide levels. (4) Islet antibodies include autoantibodies 
to glutamic-acid decarboxylase (GAD65), autoantibodies to insulin (IAA2), 
autoantibodies to the tyrosine phosphatase IA-2 and IA2B, autoantibodies to zinc 
transporter 8 (ZnT8), (5) IFNα may induce autoimmunity and therefore measure-
ment of islet antibodies should be considered before and after IFNα therapy  
in high risk patients, and in patients with suspicion of T1D after initiation of IFNα.
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for diabetes (prior to IFNα therapy) and periodic monitoring of 
blood glucose (BG) should be performed during and after IFNα 
treatment.
How?
According to ADA guidelines, the standard screening test for 
diabetes is fasting plasma Glucose (FPG) (198). The 75-gr 
oral glucose test (OGT) should be considered in patients with 
pre-diabetes (fasting blood sugar (FBS) 100–125  mg/dL or 
6–6.9 mmol/L) or high risk of diabetes.
HbA1c is an important tool for follow-up of diabetic patients; 
however, recent prospective studies have shown a continuous 
association between HbA1c at baseline and subsequent diabe-
tes. Therefore, HbA1c levels in the range of 5.7–6.4 can also be 
considered as pre-diabetes (198). Treatment with IFNα and RBV 
may induce hemolytic anemia, thereby falsely decreasing HbA1c 
levels (199). Testing for fructosamine may be valuable in these 
cases as well as in cases with known hemoglobinopathies.
How Often?
Screening for T2D is recommended every 3 years in the general 
population of individuals older than 45  years (198). In our 
opinion, screening for diabetes should be performed every 
6–12 months in patients with hepatitis C in view of the strong 
association between the two diseases. We recommend testing 
for T1D if the patient develops diabetes after initiation of IFNα 
therapy (Figure 4).
Therapeutic Considerations
Diabetes in HCV patients should be treated according to the ADA 
guidelines (198). Management of diabetes in patients with liver 
diseases is, however, complicated by the effects of drug metabolism 
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by the liver, drug interactions, and potential liver toxicity of some 
medications used to treat diabetes [For review, see Ref. (196)].
IFNα-Induced Type 1 Diabetes
To date, no consensus exists regarding continuation or with-
drawal of IFNα–RBV in IFN-induced T1D. However, reported 
cases show that IFNα–RBV are frequently stopped after diagnosis 
of IFN-induced T1D, presumably in the hope of reversing the 
diabetes. Permanent insulin treatment has been required in most 
cases of IFN-induced T1D (16); however, improvement has been 
observed in a few cases (110).
Insulin Resistance and Type 2 Diabetes
Metformin was not reported to cause hepatotoxicity and there-
fore should be considered as the drug of choice in HCV patients 
with IR or T2D. Although there is no clear evidence that treat-
ment with metformin will increase the sustained viral response 
in HCV patients, there is increasing evidence that metformin is 
independently associated with reduced risk for HCC and liver-
related death/transplantation (157, 177, 178, 200). The use of 
metformin, however, is not recommended in advanced hepatic 
disease because of increased risk for lactic acidosis (201).
Use of Metformin for other liver pathologies associated with 
IR, such as NAFLD, did not improve hepatic histopathology 
(202). By contrast, recent studies on another class of insulin 
sensitizers  –  thiazolidinediones (TZDs)  –  in NAFLD showed 
improvement in ALT and liver histology [for review, see Ref. 
(203)]. Sumie et al. assessed the effect of pioglitazone in patients 
with HCV-induced HCC and found no effect on recurrence free 
survival (204). Nevertheless, the treatment improved the IR (204). 
Yet, due to reported cases of acute cholestatic hepatitis (205, 206), 
TZD use is not recommended in advanced liver cirrhosis.
Glucosidase inhibitors act directly on the GI tract and in a 
recent placebo-controlled cross over study in patients with grade 
1–2 hepatic encephalopathy, acarbose decreased both fasting 
and postprandial glucose (207). Acarbose increases the risk of 
hyperammonemia (208), and can induce mild transient elevation 
of ALT. Rare reversible cases of severe liver disease have been 
reported [for review, see Ref. (209)], and therefore, it should be 
used with caution.
Glucagon-like peptide-1 (GLP-1) is a gut-derived incretin 
hormone that stimulates insulin secretion. Dipeptidyl pepti-
dase-4 (DPP-4) inhibitors increase incretin hormone levels, 
such as GLP-1. Itou et  al. demonstrated that the serum GLP-1 
levels were significantly decreased in HCV patients compared to 
control group and HBV group; and that DPP-4 expression was 
significantly increased in the ileum, liver, and serum in the HCV 
group. The authors concluded that altered expression of GLP-1 
may be involved in the development of HCV-associated glucose 
intolerance (210). Recent studies on GLP-1 have shown a slowing 
of the progression of NAFLD by direct effects on lipid metabolism 
in hepatocytes, and on inflammation in the liver. DPP-4 inhibitors 
may also affect hepatic pathways of fat elimination [for review, 
see Ref. (211, 212)]. A case-control study assessed the efficacy 
and safety of DPP-4 inhibitors in HCV patients (16 patients with 
T2D, included 3 patients with hepatic cirrhosis) and reported a 
reduction in HbA1C without side effects (213). Further larger 
studies are needed to support their use in patients with advanced 
hepatic diseases.
There are no trials examining the safety of sulfonylureas (SUs) 
in patients with chronic liver diseases. The use of SU with short 
half-life is generally considered safe in patients with liver disease 
(196). However, close monitoring of BG is necessary since there 
might be increased risk of hypoglycemia. SUs are metabolized by 
the liver and excreted by the kidneys, and their use is contraindi-
cated in advanced liver diseases.
Insulin has been considered as the drug of choice in patients 
with diabetes and decompensated liver disease due to short 
half-life to prevent hypoglycemia and hyperglycemia by frequent 
adjustment of the doses. However, a nested case-control study 
conducted in Japan found that use of insulin and second-gener-
ation SU were independent variables associated with incidence 
of HCC (OR =  2.96 95% confidence interval 1.29–6.82) (214). 
Other studies showed that use of metformin was associated with 
reduced risk of HCC compared with SUs and insulin (215, 216). 
A meta-analysis of observational studies reported that insulin 
and SU increased the risk for HCC, while metformin reduced the 
risk, and TDZs did not change it (217). Prospective studies are 
required to assess the link between exogenous insulin therapy and 
SU, and the risk for HCC.
Conclusion
Hepatitis C and DM are chronic diseases with high global 
prevalence of epidemic proportions. The association between 
hepatitis C and DM has been substantiated by numerous studies 
in the past two decades and represents a two-way association. 
On the one hand, HCV infection triggers diabetes, mostly type 
2 but occasionally (especially in patients treated with IFNα) type 
1 diabetes; and, on the other hand, diabetes worsens hepatitis C 
outcomes, including increasing the risk for cirrhosis and HCC. 
Mechanistic studies support the hypothesis that HCV infection 
leads to defects in insulin signaling pathways, and that direct 
effects of HCV on the beta cells are possible. Metformin is the 
drug of choice in chronic HCV infection as data provided show 
a significant reduction in the risk for HCC. Further studies 
are needed to assess the long-term effect of TDZs and DPP-4 
inhibitors on glycemic control in HCV patients, and the effects 
of insulin and SU on cancer progression.
In the light of these data, it is essential that physicians caring 
for HCV patients are aware of the high risk for T2D and T1D 
and that they screen HCV patients for diabetes. In addition, the 
presence of diabetes in an HCV patient should alert the clinician 
to the possibility of worse outcomes. It remains to be determined 
whether the new non-interferon-based therapeutic regimens for 
chronic HCV infection (such as protease inhibitors) will reduce 
the frequency of diabetes in HCV patients or improve glycemic 
control if diabetes has already developed.
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